Researchers in Denmark have developed a new assay to test for the tumour markers that point to bladder cancer.
The Danish Cancer Society and the Herlev University Hospital of Copenhagen teamed up to modify the MS-MLPA (methylation specific-multiplex ligation-dependent probe amplification) assay so it can be used with short synthetic probes.
Paired tumour and urine samples showed identical marker patterns in most cases, leading researchers to suggest that it can be used for non-invasive diagnosis and disease monitoring.
MS-MLPA screens multiple target sequences simultaneously – however, it is not available commercially, and probe design has been limited by the difficulty of synthesising long nucleotides.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData